Abstract

Abstract The composition of the proteome varies significantly across different tissues and disease states creating a challenge of how best to compare expression levels of each protein across these tissue types. Traditionally, a median approach to normalization has been used, but this could obscure meaningful biological differences between tissues. Here, we present a quantitative proteomic study analyzing proteome composition across tumor and normal tissues in order to assess normalization methods. Human proteomes covering 7 cancer indications (244 samples) and 12 normal tissue organs (370 samples) were analyzed by data-independent acquisition mass spectrometry. On average, over 8,000 proteins were quantified across the study cohorts. Comparison of proteomes revealed an average of 11.4% higher protein identification in tumors compared to matched normal tissues (6 tumor types all p<0.003). Tissue origin strongly influenced proteome composition, most notably in bone marrow, while cancer tissues displayed less proteomic composition variation than normal tissues. Compared to global median normalization, riBAQ and tissue-specific quantile normalization reduced technical variances while maintaining biological differences between tissue types. By revealing tissue-specific proteome signatures as well as systemic proteomic alterations in tumors, this study lays the groundwork for appropriate comparative approaches accounting for tissue origins, and establishes a framework for discovery of tissue-specific biomarkers, which may facilitate the development of novel diagnostic and prognostic tests, and guide therapeutic interventions for cancer. Citation Format: Ying Zheng, Lindsay Olita, McIver Nivens, Abby Chiang, Shreya Ahuja, Matthew Glover, John Bullen, Elaine Hurt, Wenyan Zhong. Mass spectrometry-based proteomics profiling reveals differential proteome composition in tumor and normal tissues, with implications for normalization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2285.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call